PMC10061119_01
The treatment process and clinical outcome of the patient who achieved a pathologic complete response to conversion therapy. (A) Computed tomography scan shows the different stages of the primary lesions over time. (B) PD-L1 assay of the primary lesion on needle biopsy by immunohistochemical staining with DAKO 22C3 antibody. Magnification, x200. (C) Pathological results of the primary specimens at baseline and after treatment with chemoimmunotherapy. Magnification, x200. (D) Illustrating the timeline of the treatment course of the patient.
fonc-13-1150931-g001.jpg
PMC10061119_01_fonc-13-1150931-g001.jpg
f1
An abdominal computed tomography (CT) scan showed the circumferential wall of the lower section of the esophagus, cardiac and corpus thickening in the portal phase, and delayed enhancement of the thickening esophagus and stomach wall and perigastric lymph nodes ( Figure 1A ). Table 1 ). The tumor mutational burden (TMB) was 2.25 mut/Mb, defined as TMB-low. The IHC results showed that the PD-L1 CPS of the tissue sample was 80-90 and the PD-L1 TPS was about 5%, indicating high PD-L1 expression ( Figure 1B ). After four-cycle treatment with camrelizumab (200 mg, day 1, i.v.), apatinib (250 mg, daily, oral), S-1 (80 mg/day, days1-14, oral), and abraxane (200 mg, days 1 and 8, i.v.), CT scans in January 2020 showed lesion shrinkage in the esophagus, stomach, and perigastric lymph nodes ( Figure 1A ). The histological assessement revealed severe necrosis and fibrosis. ( Figure 1C ). The entire course of the clinical treatment is illustrated in  Figure 1D .